P080 (0071) ANALYSIS OF OUTCOMES AND PROGNOSTIC FACTORS OF 165 NEWLY DIAGNOSED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA

P080 (0071) ANALYSIS OF OUTCOMES AND PROGNOSTIC FACTORS OF 165 NEWLY DIAGNOSED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA

Bibliographic Details
Format:	Article
Language:	English
Published:	Wiley 2018-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000547925.63835.c0

Similar Items

Prognostic Factors for Clinical Outcomes in Patients with Newly Diagnosed Advanced-stage Hodgkin Lymphoma: A Nationwide Retrospective Study
by: Chieh-Lin Jerry Teng, et al.
Published: (2022-08-01)

P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
by: Alexia Piperidou, et al.
Published: (2022-10-01)

P101 (0149) PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN PLUS AVD IN PEDIATRIC PATIENTS WITH ADVANCED STAGE NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

Usefulness of BATF3 Immunohistochemistry in Diagnosing Classical Hodgkin Lymphoma
by: Julian Benckendorff, et al.
Published: (2021-06-01)

Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
by: Arina Martynchyk, et al.
Published: (2023-10-01)

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
by: Pamela B Allen, et al.
Published: (2017-09-01)

Genetics of classical Hodgkin Lymphoma
by: Gianluca Schiavoni, et al.
Published: (2018-06-01)

P014: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
by: Rita Costa E. Sousa, et al.
Published: (2022-10-01)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
by: Irene Biasoli, et al.
Published: (2023-11-01)

Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
by: Vasileios Georgoulis, et al.
Published: (2023-06-01)

Prognostic significance of elevated D-dimer level in classical Hodgkin's Lymphoma
by: Waseem F Al-Tameemi, et al.
Published: (2023-01-01)

Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma
by: Kuang Z, et al.
Published: (2021-12-01)

Composite follicular lymphoma and classic Hodgkin lymphoma
by: Han-Na Kim, et al.
Published: (2022-01-01)

P1093: A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED-STAGE HODGKIN LYMPHOMA.
by: R. Rask Kragh Jørgensen, et al.
Published: (2022-06-01)

Serum Procalcitonin Levels in Newly Diagnosed Hodgkin Lymphoma: Correlation with Other Inflammatory Biomarkers
by: Alexia Piperidou, et al.
Published: (2022-09-01)

Degradation of p0071 and p120-catenin during adherens junction disassembly by Leptospira interrogans
by: Romina Tokumon, et al.
Published: (2023-09-01)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: Nesreen Ali, et al.
Published: (2023-08-01)

Controversies in the Treatment of Classical Hodgkin Lymphoma
by: Dennis A. Eichenauer, et al.
Published: (2018-10-01)

Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma
by: Claire Lamaison, et al.
Published: (2022-10-01)

The Grey Zones of Classic Hodgkin Lymphoma
by: Jan Bosch-Schips, et al.
Published: (2022-01-01)

Classical Hodgkin’s Lymphoma Presenting as Erythroderma
by: Kumar Parimalam, et al.
Published: (2022-11-01)

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
by: Razan Mohty, et al.
Published: (2021-07-01)

HLA-G expression and role in advanced-stage classical Hodgkin lymphoma
by: G. Caocci, et al.
Published: (2016-04-01)

P018 (0139) GATA3 EXPRESSION DISTINGUISHES CLASSIC HODGKIN LYMPHOMA FROM NODULAR LYMPHOCYTE HODGKIN LYMPHOMA
Published: (2018-10-01)

P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study
by: Luciana Vinti, et al.
Published: (2022-10-01)

Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma
by: Victoria Menéndez, et al.
Published: (2024-01-01)

Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience
by: Alberto Garaventa, et al.
Published: (2022-03-01)

P007 (0043) TARC IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

P005 (0036) THE ROLE OF TCF3 IN CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

A Rare Case of Classical Hodgkin Lymphoma Diagnosed 10 Years after Liver Transplant
by: L. Zhang, et al.
Published: (2017-10-01)

Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma
by: Chen Jiang, et al.
Published: (2024-01-01)

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
by: Kristiina Karihtala, et al.
Published: (2020-04-01)

P1085: EVALUATION OF GONADAL FUNCTION IN YOUNG WOMEN DIAGNOSED WITH HODGKIN AND NON-HODGKIN LYMPHOMA
by: A. N. Georgopoulou, et al.
Published: (2022-06-01)

P014 (0098) CD47 IS EXPRESSED ON HODGKIN REED STERNBERG CELLS IN CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
by: Mikalai Katsin, et al.
Published: (2023-12-01)

Current directions in the treatment of classical Hodgkin lymphoma
by: Frank G. Keller, et al.
Published: (2023-11-01)

Treatment Of Classical Hodgkin Lymphoma: The State Of The Art
by: Carmino Antonio de Souza, et al.
Published: (2023-10-01)

Bone marrow involvement by classic Hodgkin lymphoma
by: Mohammad Barouqa, et al.
Published: (2022-05-01)

Evolution of drug therapy for classical Hodgkin lymphoma
by: N. Y. Samaneva, et al.
Published: (2022-09-01)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
by: Soyoung Im, et al.
Published: (2022-11-01)